Open | - |
Close | - |
Volume / Avg. | 7.000 / 201.165K |
Day Range | - - - |
52 Wk Range | 0.590 - 5.400 |
Market Cap | $3.916M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 73 |
Short Interest | 0.26% |
Days to Cover | 1 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of NeuBase Therapeutics (NASDAQ: NBSE) through any online brokerage.
Other companies in NeuBase Therapeutics’s space includes: Tharimmune (NASDAQ:THAR), Synaptogenix (NASDAQ:SNPX), Cyclacel Pharmaceuticals (NASDAQ:CYCC), Geovax Labs (NASDAQ:GOVX) and Finch Therapeutics Gr (NASDAQ:FNCH).
The latest price target for NeuBase Therapeutics (NASDAQ: NBSE) was reported by Oppenheimer on Friday, October 21, 2022. The analyst firm set a price target for 0.00 expecting NBSE to fall to within 12 months (a possible -100.00% downside). 0 analyst firms have reported ratings in the last year.
The stock price for NeuBase Therapeutics (NASDAQ: NBSE) is $1.05 last updated March 18, 2024 at 6:05 PM EDT.
There are no upcoming dividends for NeuBase Therapeutics.
NeuBase Therapeutics’s Q2 earnings are confirmed for Thursday, May 9, 2024.
There is no upcoming split for NeuBase Therapeutics.
NeuBase Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.